SCHEMBL2911263

SCHEMBL2911263

Cc1c(N2CCN(C)CC2)ccc2cnc(Nc3ccc4cn[nH]c4c3)nc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 13/20 0.65
PDGFRA P16234 13/20 0.65
EGFR P00533 3/20 0.59
FGFR1 P11362 2/20 0.59
CHEK1 O14757 1/20 0.51
AURKA O14965 1/20 0.51
DAPK3 O43293 1/20 0.51
JAK2 O60674 1/20 0.51
PRKD3 O94806 1/20 0.51
MAP4K4 O95819 1/20 0.51
PAK4 O96013 1/20 0.51
ABL1 P00519 1/20 0.51
NTRK1 P04629 1/20 0.51
LCK P06239 1/20 0.51
FYN P06241 1/20 0.51
CSF1R P07333 1/20 0.51
RET P07949 1/20 0.51
IGF1R P08069 1/20 0.51
MET P08581 1/20 0.51
PIM1 P11309 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2921459 0.92 PDGFRB (0.54) PDGFRBPDGFRAEGFRFGFR1WEE1
SCHEMBL2921831 0.91 PDGFRB (0.54) PDGFRBPDGFRAEGFRFGFR1WEE1
SCHEMBL2917218 0.90 PDGFRB (0.63) PDGFRBPDGFRAEGFRFGFR1ROCK1
SCHEMBL2912670 0.89 PDGFRB (0.65) PDGFRBPDGFRAEGFRFGFR1BTK
SCHEMBL2912102 0.88 SYK (0.61) PDGFRBPDGFRAEGFRFGFR1JAK3
SCHEMBL2917783 0.85 PDGFRB (0.49) PDGFRBPDGFRAEGFRFGFR1WEE1
SCHEMBL2922682 0.84 PDGFRB (0.48) PDGFRBPDGFRAEGFRFGFR1WEE1
SCHEMBL29793840 0.79 PDGFRB (1.00) PDGFRBPDGFRAEGFRFGFR1CHEK1
SCHEMBL26395520 0.79 PDGFRB (1.00) PDGFRBPDGFRAEGFRFGFR1CHEK1
SCHEMBL2912421 0.79 CDC7 (0.52) PDGFRBPDGFRAEGFRFGFR1CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K PDGFRB 1018/4885PDGFRA 862/4885EGFR 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.